Project Grant R24OD039898
- Federal Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded Indiana University Indianapolis $1,303,054 under the Trans-NIH Research Support program (CFDA 93.310) to conduct a two-year Project Grant (August 1, 2025–July 31, 2027) examining genetic modifiers of Down syndrome phenotypes. The project creates novel mouse models with genetically diverse backgrounds to better represent the human condition of Trisomy 21 (TS21), identifying modifier genes and...
- Federal Grant Award Summary The National Institutes of Health Office of the Director awarded University of Wisconsin–Madison a $1.49 million Project Grant under the Trans-NIH Research Support program (CFDA 93.310) on September 16, 2025, with a completion date of August 31, 2027. This research initiative focuses on developing and characterizing humanized mouse models to study Down syndrome immune responses, specifically addressing the immune dysregulation associated with trisomy 21. The project...
- Federal Project Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded $892,192 to the University of Illinois through the Trans-NIH Research Support program (CFDA 93.310) on August 1, 2025, to develop and implement community-based participatory research (CBPR) examining health disparities among young adults with Down syndrome (DS). The project, which extends through July 31, 2027, directly engages young adults with DS as research partners throughout the entire...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $451,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 1, 2025 through June 30, 2027. This R21 exploratory grant funds research to develop CRISPR interference (CRISPRi) technology tools and high-throughput screening methodologies for identifying genes on human chromosome 21 (HSA21) that...
- Federal Grant Award Summary The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded Indiana University a $435,875 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the period September 1, 2025 through August 31, 2027. The project develops and validates a novel mouse model to study vaginal exocrine function and drug-induced vaginal dryness. Vaginal dryness affects millions of women across the...
- Federal Grant Award Summary The University of New Mexico Health Sciences Center received a $419,375 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 1, 2026 through June 30, 2028. The award supports research investigating the mechanisms of vascular dysfunction in Down syndrome, with specific focus on understanding how endothelial glycocalyx depletion contributes to cardiovascular disease...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $1,257,163 Project Grant from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) effective July 1, 2025, with a completion date of June 30, 2030. The award funds research into a humanized monoclonal follicle-stimulating hormone (FSH) antibody therapeutic targeting Alzheimer's disease and co-occurring health conditions in individuals with Down...
- Federal Grant Award Summary The University of Colorado received a $430,375 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 17, 2025, with a completion date of June 30, 2027. The grant funds research investigating the association between Trisomy 21 (Down's Syndrome) and placentation defects, addressing the elevated risk of adverse pregnancy outcomes in T21 pregnancies due to...
- Federal Grant Award Summary The Include Clinical Researcher Training (ICRT) program, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), received a Project Grant award of $866,506 on September 20, 2025. Administered by Magee-Womens Research Institute and Foundation with completion scheduled for August 31, 2027, this R25 training program recruits and trains 16 post-graduate participants annually in Down Syndrome (DS)...
- Federal Project Grant Award Summary Boston Children's Hospital received a $1.27 million Project Grant (R01) from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 1, 2025 through July 31, 2027. The award supports collaborative research investigating the mechanisms through which transposable element (TE) mobilization and disrupted messenger RNA (mRNA) translation impair neural progenitor cell (NPC)...
Indiana University Indianapolis received a $692,850 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 1, 2026, through March 31, 2030. The award funds the development of novel Down syndrome mouse models designed to systematically characterize sex-specific phenotypes and their developmental origins. Specifically, the research creates new mouse models by crossing DP16 mice (which carry triplicated genes mimicking trisomy 21) with Four Core Genotype (FCG) mice, which allows researchers to separately isolate the contributions of gonadal sex and sex chromosomal complement to disease manifestation. This approach addresses a critical gap in Down syndrome preclinical research, where historical male-biased models and small sample sizes have obscured sex-specific differences in disease presentation. The project will conduct systematic longitudinal analysis of hormone levels and developmental phenotypes across eight distinct mouse groups to delineate how sex-specific traits in Down syndrome emerge before and after puberty. By determining whether sex differences originate from gonadal secretions or sex chromosome gene expression, the research aims to improve the translational validity of Down syndrome mouse models and potentially inform sex-differentiated treatment approaches for individuals with Down syndrome. This work represents the first comprehensive effort to characterize the biological sources of sexual dimorphisms in Down syndrome phenotypes using a controlled genetic model.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $692.9k | 6/23/26 |